Communication Strategies for Patient Engagement

Overseen By Helen Seow, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Yale University

Disqualifiers: Active cancer treatment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

214526 Participants Needed

Trial Summary

What is the purpose of this trial?

Based on the outcomes of the initial study (NCT05348603), this optimization study will employ the most effective interventions (letters and messages) and distribute these communications to underrepresented minorities to further promote interest in research. Optimized language will be distributed in English, Spanish, Portuguese, Chinese, Arabic, or Haitian Creole, based on preferred language identified in the patient profile in an electronic medical records system.

Research Team

Brian Smith, MD

Principal Investigator

Yale University

Eligibility Criteria

This trial is for individuals from underrepresented minorities who are interested in research participation. It aims to engage patients whose preferred language, as noted in their electronic medical records, includes English, Spanish, Portuguese, Chinese, Arabic, or Haitian Creole.

Inclusion Criteria

Has not set up a research profile

Has an account with the online patient portal

Has logged into the online patient portal at least once in the past year

Exclusion Criteria

Currently enrolled in a clinical trial

Opted out of research

I am currently receiving treatment for cancer.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive either optimized or generic letters and messages to promote research participation

12 months

Follow-up

Participants are monitored for their interest and participation in research studies

12 months

Treatment Details

Interventions

• Electronic Health Record Strategies

Trial Overview The study tests the effectiveness of different communication strategies (traditional and optimized letters/messages) to increase diverse participation in research. The content will be tailored based on outcomes from a previous study and distributed according to the patient's preferred language.

Participant Groups

Group I: Optimized Message Experimental Treatment 1 Intervention

Participants receive an 'optimized' message.

Group II: Optimized Letter + Optimized Message Experimental Treatment 2 Interventions

Participants receive both a 'optimized' letter and a 'optimized' message.

Group III: Optimized Letter Experimental Treatment 1 Intervention

Participants receive an 'optimized' letter.

Group IV: Generic Letter + Generic Message Experimental Treatment 2 Interventions

Participants receive both a 'usual' letter and a 'usual' message.

Group V: Generic Letter Active Control 1 Intervention

Participants receive a 'usual' letter.

Group VI: Generic Message Active Control 1 Intervention

Participants receive a 'usual' message.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

Food and Drug Administration (FDA)

Collaborator

Trials

184

Recruited

1,553,000+